Hepatitis B screening with conventional and emerging biomarkers

Abstract

Long-term treatment of chronic hepatitis due to hepatitis B virus (HBV) with nucleotide/nucleoside analogues (NUC) can stop the progression of the disease and the development of liver cirrhosis with its complications, including the appearance hepatocellular carcinoma (HCC); and on many specific occasions, prevent HBV reactivation, the development of severe acute hepatitis, and in some cases, acute liver failure. However, the use of NUC does not achieve a functional cure, that is, the disappearance of the surface antigen of the hepatitis B virus (HBsAg), and the most important thing is that there are still no known markers that allow us to define in which Antiviral treatment can be withdrawn at this time.